ABSTRACT
The management of patients with brain oligometastases is complex and relies on specific reasoning compared to extracranial oligometastases. The levels of evidence are still low because patients with brain oligometastases are frequently excluded from randomized clinical trials. Stereotactic radiotherapy should be preferred in this indication over whole brain irradiation, both for patients with metastases in place and for those who have undergone surgery. The decision of local treatment and its timing must be a multidisciplinary reflection taking into account the histological and molecular characteristics of the tumor as well as the intracranial efficacy of the prescribed systemic treatments. Great caution must be observed when using stereotactic radiotherapy and concomitant systemic treatments because interactions are still poorly documented. We present the recommendations of the French society of radiation oncology on the management of brain oligometastatic patients with radiotherapy.
Subject(s)
Neoplasms , Radiation Oncology , Radiosurgery , Humans , Neoplasms/pathology , Brain/pathology , Radiosurgery/adverse effects , Dose Fractionation, RadiationABSTRACT
Translational research in radiation oncology is undergoing intense development. An increasingly rapid transfer is taking place from the laboratory to the patients, both in the selection of patients who can benefit from radiotherapy and in the development of innovative irradiation strategies or the development of combinations with drugs. Accelerating the passage of discoveries from the laboratory to the clinic represents the ideal of any translational research program but requires taking into account the multiple obstacles that can slow this progress. The ambition of the RadioTransNet network, a project to structure preclinical research in radiation oncology in France, is precisely to promote scientific and clinical interactions at the interface of radiotherapy and radiobiology, in its preclinical positioning, in order to identify priorities for strategic research dedicated to innovation in radiotherapy. The multidisciplinary radiotherapy teams with experts in biology, medicine, medical physics, mathematics and engineering sciences are able to meet these new challenges which will allow these advances to be made available to patients as quickly as possible.
Subject(s)
Neoplasms , Radiation Oncology , France , Humans , Neoplasms/radiotherapy , Radiobiology , Translational Research, BiomedicalABSTRACT
PURPOSE: The Varian TrueBeam STx linac can be equipped with BrainLAB stereotactic cones and ExacTrac imaging system for SRS treatments. However, these two third-party systems lack integration in a self-performance diagnosis tool dedicated to the SRS platform. The aim of this work was to design and automate essential geometric tests considering the complete set of cones with diameter range from 4 to 15 mm. METHODS: EPID-based tests were focused on the cone alignment, the radiation isocentricity and the isocenters congruence. Images acquired with or without the BrainLAB pointer were analysed using the Hough transform and morphological filtering operations, after assessment of the algorithm accuracy using simulated images. The new Machine QA program was experimented over one year. RESULTS: A subpixel resolution of 0.02 mm was found for the circular-field center detection algorithm. The tests results did not depend on the pointer location. The maximum deviations reported were in accordance with the AAPM SRS guidelines. The accurate localization of the linac radiation isocenter allowed for guidance of the ExacTrac calibration. A misalignment reaching 0.2 mm was measured for all cones but one, highlighting the benefit of systematizing this control before each patient SRS treatment. CONCLUSION: An effective in-house QA program dedicated to SRS cones was developed to supplement the standard machine performance check on our mixed SRS platform. Specific geometric tests even include the smallest 4-mm cone, which could be of great interest for future clinical indications such as the radiosurgery of functional disorders.
Subject(s)
Radiosurgery , Automation , Humans , Particle Accelerators , Phantoms, Imaging , Quality Control , Radiosurgery/methodsABSTRACT
We present the update of the recommendations of the French society for radiation oncology on radiation therapy for the management of brain metastases. It has evolved in recent years and has become more complex. As the life expectancy of patients has increased and retreatments have become more frequent, side effects must be absolutely avoided. Cognitive side effects must in particular be prevented, and the most modern radiation therapy techniques must be used systematically. New prognostic classifications specific to the primary tumour of patients, advances in imaging and radiation therapy technology and new systemic therapeutic strategies, are making treatment more relevant. Stereotactic radiation therapy has supplanted whole-brain radiation therapy both for patients with metastases in place and for those who underwent surgery. Hippocampus protection is possible with intensity-modulated radiation therapy. Its relevance in terms of cognitive functioning should be more clearly demonstrated but the requirement for its use is constantly increasing. New targeted cancer treatment therapies based on the nature of the primitive have complicated the notion of the place and timing of radiation therapy and the discussion during multidisciplinary care meeting to indicate the best sequences is becoming a challenging issue as data on the interaction between treatments remain to be documented. In the end, although aimed at patients in the palliative phase, the management of brain metastases is one of the locations for which technical reflection is the most challenging and treatment become increasingly personalized.
Subject(s)
Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/prevention & control , Cognition Disorders/prevention & control , Cranial Irradiation , France , Humans , Molecular Targeted Therapy , Palliative Care , Prognosis , Radiation Injuries/prevention & control , Radiation Oncology , Radiosurgery , Radiotherapy, Intensity-Modulated , Societies, MedicalABSTRACT
We present the updated recommendations of the French Society for Radiation Oncology on benign intracranial tumours. Most of them are meningiomas, vestibular schwannomas, pituitary adenomas, craniopharyngiomas, and glomus tumours. Some grow very slowly, and can be observed without speciï¬c treatment, especially if they are asymptomatic. Symptomatic or growing tumours are treated by surgery, which is the reference treatment. When surgery is not possible, due to the location of the lesion, or general conditions, radiotherapy can be applied, as it is if there is a postoperative growing residual tumour, or a local relapse. Indications have to be discussed at a multidisciplinary panel, with precise evaluation of the benefit and risks of the treatments. The techniques to be used are the most modern ones, as multimodal imaging and image-guided radiation therapy. Stereotactic treatments, using fractionated or single doses depending on the size or the location of the tumours, are commonly realized, to avoid as much a possible the occurrence of late side effects.
Subject(s)
Brain Neoplasms/radiotherapy , Adenoma/radiotherapy , Brain Neoplasms/surgery , Craniopharyngioma/radiotherapy , France , Glomus Tumor/radiotherapy , Humans , Meningeal Neoplasms/radiotherapy , Meningioma/radiotherapy , Multimodal Imaging , Neuroma, Acoustic/radiotherapy , Paraganglioma/radiotherapy , Pituitary Neoplasms/radiotherapy , Radiation Oncology , Radiotherapy Dosage , Radiotherapy, Image-Guided , Societies, MedicalABSTRACT
PURPOSE: The determination of output factors in small field dosimetry is a crucial point, especially when implementing stereotactic radiotherapy (SRT). Herein, a working group of the French medical physicist society (SFPM) was created to collect small field output factors. The objective was to gather and disseminate information on small field output factors based on different detectors for various clinical SRT equipment and measurement configurations. METHOD: Participants were surveyed for information about their SRT equipment, including the type of linear particle accelerator (linac), collimator settings, measurement conditions for the output factors and the detectors used. Participants had to report both the ratio of detector readings and the correction factors applied as described in the IAEA TRS-483 code of practice for nominal field sizes smaller or equal to 3 cm. Mean field output factors and their associated standard deviations were calculated when data from at least 3 linacs were available. RESULTS: 23 centres were enrolled in the project. Standard deviations of the mean field output factors were systematically smaller than 1.5% for field sizes larger or equal to 1 cm and reached 5% for the smallest field size (0.5 cm). Deviations with published data were smaller than 2% except for the 0.5 cm circular fixed aperture collimator of the CyberKnife where it reached 3.5%. CONCLUSION: These field output factor values obtained via a large multicentre study can be considered as an external cross verification for any radiotherapy centre starting a SRT program and should help minimize systematic errors when determining small field output factors.
Subject(s)
Photons , Radiosurgery , Humans , Monte Carlo Method , Particle Accelerators , RadiometryABSTRACT
The arrival of new hybrid radiotherapy machines with MRI or PET is announced as a milestone in radiotherapy management. Based on recent literature, we will describe the contribution of each of these modalities and the technological challenges that have already been or are still to be addressed.
Subject(s)
Equipment Design , Magnetic Resonance Imaging, Interventional/instrumentation , Multimodal Imaging/methods , Particle Accelerators , Positron-Emission Tomography/instrumentation , Radiotherapy, Image-Guided/instrumentation , Humans , Magnetic Resonance Imaging, Interventional/trends , Multimodal Imaging/trends , Positron-Emission Tomography/trends , Radiotherapy, Image-Guided/trendsABSTRACT
PURPOSE: Bilateral pulmonary radiotherapy in children and young adults aims to reduce the recurrence of lung metastases. The radiation field includes liver tissue, which is sensitive to even low radiation doses. We investigated the feasibility of respiratory gating radiotherapy using voluntary deep inspiration breath hold and its toxicity in these patients. PATIENTS AND METHOD: A retrospective clinical review was conducted for all patients who had undergone bilateral pulmonary radiotherapy, with or without deep inspiration breath hold, treated in our institution between October 1999 and May 2012. A dosimetric study was conducted on seven consecutive children using 4D-scan data on free-breathing and a SpiroDyn'RX-system-scan on deep inspiration breath hold. A radiation treatment of 20Gy was simulated. RESULTS: Concerning the clinical study, seven patients of mean age 11.9 years (range: 4.9-21.1 years) were treated with free-breathing and ten patients of mean age 15.6 years (range: 8.6-19.7 years) were treated with deep inspiration breath hold for mainly Ewing sarcoma and nephroblastoma. Within six months of radiotherapy, all patients experienced mild liver toxicity (grade 1 or 2 altered levels of alanine/aspartate aminotransferase [n=8 of 9] or cholestasis [n=1 of 9]), which resolved completely with no difference between deep inspiration breath hold and free-breathing technique. Over a median follow-up of 2.6 years (range: 0.1-9.3 years), four patients died from disease progression (mean 1.5 years post-radiotherapy [range: 1.1-1.6 years]) and three experienced grade III-V lung toxicity. Concerning the dosimetric study, the irradiated liver volume was significantly lower with deep inspiration breath hold than free-breathing, for each isodose (V5: 73.80% versus 86.74%, P<0.05; V20: 5.70% versus 26.44%, P<0.05). CONCLUSIONS: The dosimetric data of respiratory-gated bilateral pulmonary radiotherapy showed a significantly spare of normal liver tissue. Clinical data showed that this technique is feasible even in young children. However, no liver toxicity difference between deep inspiration breath hold and free-breathing was shown.
Subject(s)
Bone Neoplasms/radiotherapy , Kidney Neoplasms/radiotherapy , Lung Neoplasms/prevention & control , Lung Neoplasms/radiotherapy , Neoplasm Recurrence, Local/prevention & control , Neoplasm Recurrence, Local/radiotherapy , Sarcoma, Ewing/prevention & control , Sarcoma, Ewing/radiotherapy , Wilms Tumor/prevention & control , Wilms Tumor/radiotherapy , Adolescent , Bone Neoplasms/pathology , Child , Child, Preschool , Feasibility Studies , Humans , Kidney Neoplasms/pathology , Lung Neoplasms/secondary , Radiation Dosage , Radiotherapy/methods , Respiration , Retrospective Studies , Sarcoma, Ewing/secondary , Wilms Tumor/secondary , Young AdultABSTRACT
Radiotherapy for brain metastases has become more multifaceted. Indeed, with the improvement of the patient's life expectancy, side effects must be undeniably avoided and the retreatments or multiple treatments are common. The cognitive side effects should be warned and the most modern techniques of radiation therapy are used regularly to reach this goal. The new classifications of patients with brain metastases help guiding treatment more appropriately. Stereotactic radiotherapy has supplanted whole brain radiation therapy both for patients with metastases in place and for those who underwent surgery. Hippocampus protection is possible with intensity-modulated radiotherapy. Its relevance in terms of cognitive functioning should be more clearly demonstrated but the requirement, for using it, is increasingly strong. While addressing patients in palliative phase, the treatment of brain metastases is one of the localisations where technical thinking is the most challenging.
Subject(s)
Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Cranial Irradiation/methods , Age Factors , Brain/radiation effects , Cognition Disorders/etiology , Cognition Disorders/prevention & control , Combined Modality Therapy , Cranial Irradiation/adverse effects , Cranial Irradiation/standards , Dose Fractionation, Radiation , Humans , Organs at Risk , Radiation Injuries/prevention & control , Radiosurgery/adverse effects , Radiosurgery/methods , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Intensity-Modulated/adverse effects , Radiotherapy, Intensity-Modulated/methodsABSTRACT
PURPOSE: The use of small photon fields is now an established practice in stereotactic radiosurgery and radiotherapy. However, due to a lack of lateral electron equilibrium and high dose gradients, it is difficult to accurately measure the dosimetric quantities required for the commissioning of such systems. Moreover, there is still no metrological dosimetric reference for this kind of beam today. In this context, the first objective of this work was to determine and to compare small fields output factors (OF) measured with different types of active detectors and passive dosimeters for three types of facilities: a CyberKnife(®) system, a dedicated medical linear accelerator (Novalis) equipped with m3 microMLC and circular cones, and an adaptive medical linear accelerator (Clinac 2100) equipped with an additional m3 microMLC. The second one was to determine the kQclin,Qmsr (fclin,fmsr) correction factors introduced in a recently proposed small field dosimetry formalism for different active detectors. METHODS: Small field sizes were defined either by microMLC down to 6 × 6 mm(2) or by circular cones down to 4 mm in diameter. OF measurements were performed with several commercially available active detectors dedicated to measurements in small fields (high resolution diodes: IBA SFD, Sun Nuclear EDGE, PTW 60016, PTW 60017; ionizing chambers: PTW 31014 PinPoint chamber, PTW 31018 microLion liquid chamber, and PTW 60003 natural diamond). Two types of passive dosimeters were used: LiF microcubes and EBT2 radiochromic films. RESULTS: Significant differences between the results obtained by several dosimetric systems were observed, particularly for the smallest field size for which the difference in the measured OF reaches more than 20%. For passive dosimeters, an excellent agreement was observed (better than 2%) between EBT2 and LiF microcubes for all OF measurements. Moreover, it has been shown that these passive dosimeters do not require correction factors and can then be used as reference dosimeters. Correction factors for the active detectors have then been determined from the mean experimental OF measured by the passive dosimeters. CONCLUSIONS: Four sets of correction factors needed to apply the new small field dosimetry formalism are provided for several active detectors. A protocol for small photon beams OF determination based on passive dosimeters measurements has been recently proposed to French radiotherapy treatment centers.